Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc Analyst and Investor Event Transcript

Nov 09, 2022 / 03:00PM GMT
Release Date Price: €30 (-14.11%)
Operator

Good morning, and welcome to the Arrowhead Pharmaceuticals Cardiometabolic Virtual Investor Event. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Arrowhead website following the conclusion of the event.

I'd now like to turn the call over to Vince Anzalone, Vice President of Finance and Investor Relations at Arrowhead Pharmaceuticals. Please go ahead, Vince.

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Thanks so much, Tara. And thanks, everyone, for joining us today. We're here to talk about our cardiometabolic pipeline and some exciting new data we have.

Go ahead in next slide, please. I'm Vince Anzalone, Head of Investor Relations for the company.

Next slide, please. And just reminding everybody that we will be making forward-looking statements on today's call. So please refer to our SEC filings for risk factors.

Next slide, please. Okay. So here is the general flow of today. I'll give some opening statements. Dr. Rosenson will talk

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot